期刊
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
卷 22, 期 12, 页码 6202-6212出版社
WILEY
DOI: 10.1111/jcmm.13907
关键词
5-FU; acute lymphoblastic leukemia; nucleotide metabolism; PRPP; PRPS1
资金
- National Natural Science Foundation of China [31530017, 81500112]
- Rising-Star Program from the Science and Technology Commission of Shanghai Municipality
- Outstanding Youth of Shanghai Municipal Commission of Health and Family Planning
- Science and Technology Commission of Pudong New Area Foundation
Relapse-specific mutations in phosphoribosyl pyrophosphate synthetase 1 (PRPS1), a rate-limiting purine biosynthesis enzyme, confer significant drug resistances to combination chemotherapy in acute lymphoblastic leukemia (ALL). It is of particular interest to identify drugs to overcome these resistances. In this study, we found that PRPS1 mutant ALL cells specifically showed more chemosensitivity to 5-Fluorouracil (5-FU) than control cells, attributed to increased apoptosis of PRPS1 mutant cells by 5-FU. Mechanistically, PRPS1 mutants increase the level of intracellular phosphoribosyl pyrophosphate (PRPP), which causes the apt conversion of 5-FU to FUMP and FUTP in Reh cells, to promote 5-FU-induced DNA damage and apoptosis. Our study not only provides mechanistic rationale for re-targeting drug resistant cells in ALL, but also implicates that ALL patients who harbor relapse-specific mutations of PRPS1 might benefit from 5-FU-based chemotherapy in clinical settings.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据